The safety and effectiveness of Ultomiris (ravulizumab-cwvz) as a maintenance therapy for children and adolescents with atypical hemolytic uremic syndrome (aHUS) remained unchanged even when the drug was administered at lower doses, not using the patient’s weight as a guide. That’s according to a new, small study that…
Discussion
Note: This column describes the author’s own experiences with Soliris (eculizumab). Not everyone will have the same response to treatment. Consult your doctor before starting or stopping a therapy. A sharp twitch jolted my right eye, like lightning striking. I closed my eyes, pressing my hand over the aching spot.
Becoming educated and informed about aHUS is a good first step. Here you’ll find general information about the disease, including diagnosis, symptoms, and causes.
It helps to know others have been where you are now. Here’s a collection of our columnist’s words of wisdom to help you along on your aHUS journey.
There is no cure for aHUS yet, but here you can find more information about current therapeutic approaches, as well as experimental treatments that are in the pipeline.
Get regular updates to your inbox.
